QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
NYSE:HIMS

Hims & Hers Health (HIMS) Stock Forecast, Price & News

$8.94
+0.06 (+0.68%)
(As of 05/31/2023 ET)
Compare
Today's Range
$8.71
$9.04
50-Day Range
$8.81
$12.04
52-Week Range
$3.54
$12.34
Volume
3.29 million shs
Average Volume
3.24 million shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.91

Hims & Hers Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
33.2% Upside
$11.91 Price Target
Short Interest
Healthy
16.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of Hims & Hers Health in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$8.03 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.21) to ($0.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

406th out of 1,006 stocks

Offices & Clinics Of Medical Doctors Industry

3rd out of 7 stocks


HIMS stock logo

About Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.

Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

HIMS Stock News Headlines

Hims (ED) Review
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
6 Analysts Have This to Say About Hims & Hers Health
Analyst Expectations for Hims & Hers Health's Future
Hims & Hers Stock: The Gift That Keeps On Giving
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
HIMS May 2023 7.000 call
Q1 2023 Hims & Hers Health Inc Earnings Call
Citigroup Remains a Buy on Hims & Hers Health (HIMS)
See More Headlines
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

HIMS Company Calendar

Last Earnings
5/08/2023
Today
5/31/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Offices & clinics of medical doctors
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
398
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.91
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+34.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-65,680,000.00
Pretax Margin
-9.61%

Debt

Sales & Book Value

Annual Sales
$616.37 million
Book Value
$1.49 per share

Miscellaneous

Free Float
135,597,000
Market Cap
$1.87 billion
Optionable
Optionable
Beta
0.47

Key Executives

  • Mr. Andrew DudumMr. Andrew Dudum (Age 34)
    Co-Founder, Chairman & CEO
    Comp: $2.18M
  • Ms. Melissa BairdMs. Melissa Baird (Age 45)
    Chief Operations Officer
    Comp: $800.85k
  • Ms. Irene A. Becklund (Age 38)
    Principal Accounting Officer
    Comp: $544.29k
  • Ms. Soleil Teubner Boughton (Age 44)
    Chief Legal Officer & Corp. Sec.
    Comp: $1.19M
  • Dr. Patrick Carroll M.D. (Age 65)
    Chief Medical Officer, Member of Medical Advisory Board & Director
    Comp: $828.1k
  • Mr. Yemi Okupe (Age 37)
    Chief Financial Officer
  • Mr. Brian O'Shaughnessy
    Chief Communications Officer
  • Ms. Amee Parekh
    Sr. VP of HR
  • Mr. Mike Chi
    Chief Growth Officer
  • Mr. Jonathan Spitzer C.F.A.
    Sr. VP of Investor Relations













HIMS Stock - Frequently Asked Questions

Should I buy or sell Hims & Hers Health stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HIMS shares.
View HIMS analyst ratings
or view top-rated stocks.

What is Hims & Hers Health's stock price forecast for 2023?

9 brokerages have issued twelve-month target prices for Hims & Hers Health's shares. Their HIMS share price forecasts range from $5.00 to $18.00. On average, they anticipate the company's stock price to reach $11.91 in the next year. This suggests a possible upside of 33.2% from the stock's current price.
View analysts price targets for HIMS
or view top-rated stocks among Wall Street analysts.

How have HIMS shares performed in 2023?

Hims & Hers Health's stock was trading at $6.41 on January 1st, 2023. Since then, HIMS stock has increased by 39.5% and is now trading at $8.94.
View the best growth stocks for 2023 here
.

Are investors shorting Hims & Hers Health?

Hims & Hers Health saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 20,940,000 shares, a drop of 7.0% from the April 30th total of 22,510,000 shares. Based on an average daily volume of 3,860,000 shares, the days-to-cover ratio is currently 5.4 days. Approximately 17.0% of the company's stock are sold short.
View Hims & Hers Health's Short Interest
.

When is Hims & Hers Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our HIMS earnings forecast
.

How were Hims & Hers Health's earnings last quarter?

Hims & Hers Health, Inc. (NYSE:HIMS) released its earnings results on Monday, May, 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. The firm had revenue of $190.80 million for the quarter, compared to analyst estimates of $179.07 million. Hims & Hers Health had a negative net margin of 9.65% and a negative trailing twelve-month return on equity of 18.97%. The firm's quarterly revenue was up 88.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.08) EPS.

What guidance has Hims & Hers Health issued on next quarter's earnings?

Hims & Hers Health updated its second quarter 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $200.00 million-$205.00 million, compared to the consensus revenue estimate of $183.30 million.

What is Hims & Hers Health's stock symbol?

Hims & Hers Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "HIMS."

Who are Hims & Hers Health's major shareholders?

Hims & Hers Health's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.29%), Institutional Venture Management XVI LLC (3.70%), Institutional Venture Management XV LLC (3.70%), Redpoint Management LLC (3.19%), Foresite Capital Management V LLC (1.79%) and State Street Corp (1.42%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee.
View institutional ownership trends
.

How do I buy shares of Hims & Hers Health?

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hims & Hers Health's stock price today?

One share of HIMS stock can currently be purchased for approximately $8.94.

How much money does Hims & Hers Health make?

Hims & Hers Health (NYSE:HIMS) has a market capitalization of $1.87 billion and generates $616.37 million in revenue each year. The company earns $-65,680,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

How many employees does Hims & Hers Health have?

The company employs 398 workers across the globe.

How can I contact Hims & Hers Health?

Hims & Hers Health's mailing address is 2269 CHESTNUT STREET SUITE 523, SAN FRANCISCO CA, 94123. The official website for the company is www.forhims.com. The company can be reached via phone at 415-851-0195 or via email at hims-ir@westwicke.com.

This page (NYSE:HIMS) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -